Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 5/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.47 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.47 |
| ▸ | EGFR | P00533 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 3/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 2/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | MAPK8 | P45983 | 2/20 | 0.42 |
| ▸ | MAPK9 | P45984 | 2/20 | 0.42 |
| ▸ | MAPK10 | P53779 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20595308 | 0.94 | MEN1 (0.48) | MEN1KMT2AMAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL23326235 | 0.91 | PIK3CA (0.54) | MEN1KMT2AMAPTALDH1A1CSNK1A1 | |
| SCHEMBL20595298 | 0.86 | PIK3CA (0.46) | MEN1KMT2AMAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL20595368 | 0.84 | MEN1 (0.50) | MEN1KMT2AMAPTPIK3CALMNA | |
| SCHEMBL23344437 | 0.83 | PIK3CA (0.47) | MEN1KMT2AMAPTSMN1; SMN2PIK3CA | |
| SCHEMBL23326195 | 0.82 | MEN1 (0.51) | MEN1KMT2AMAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL20595313 | 0.82 | CDK8 (0.52) | MEN1KMT2AMAPTPIK3CALMNA | |
| SCHEMBL23344475 | 0.79 | PIK3CA (0.52) | PIK3CAAURKBMAPK8MAPK9MAPK10 | |
| SCHEMBL23344450 | 0.79 | KCNQ3 (0.45) | SMN1; SMN2PIK3CANPC1RAB9AMAPK8 | |
| SCHEMBL23344463 | 0.78 | MEN1 (0.55) | MEN1KMT2AMAPTALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11117894-B2 | Pyridopyrazine compounds and uses thereof | CITY OF HOPE (US) | 2021-09-14 | — | — | US | disclosed |
| US-11117894-B2 | Pyridopyrazine compounds and uses thereof | CITY OF HOPE (US) | 2021-09-14 | — | — | US | disclosed |
| US-20210139476-A1 | PYRIDOPYRAZINE COMPOUNDS AND USES THEREOF | NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS (GR) | 2021-05-13 | — | — | US | disclosed |
| US-20210139476-A1 | PYRIDOPYRAZINE COMPOUNDS AND USES THEREOF | NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS (GR) | 2021-05-13 | — | — | US | disclosed |
| WO-2018237190-A1 | PYRIDOPYRAZINE COMPOUNDS AND USES THEREOF | CITY OF HOPE (US) | 2018-12-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11117894-B2 | Pyridopyrazine compounds and uses thereof | PDXK, DPYD, PNPO | MEN1 4106/4885KMT2A 2474/4885MAPT 2937/4885 |
| US-20210139476-A1 | PYRIDOPYRAZINE COMPOUNDS AND USES THEREOF | PDXK, DPYD, PNPO | MEN1 4106/4885KMT2A 2474/4885MAPT 2937/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.